The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study

Sofia Dahlberg1, Ulf Schött2,3, Thomas Kander2,3

  • 1Division of Anaesthesia and Intensive Care, Department of Clinical Sciences, Lund University, SE-22184, Lund, Sweden. sofia.irma.dahlberg@gmail.com.

Journal of Intensive Care
|January 19, 2021
PubMed

Insights

Vitamin K administration in critically ill patients with elevated PT-INR (1.3-1.9) led to a slightly greater reduction in PT-INR compared to controls. Further research is needed to identify patient groups that benefit most from vitamin K.

Area of Science:

  • Critical Care Medicine
  • Hematology
  • Pharmacology

Background:

  • Vitamin K deficiency is common in critically ill patients with slightly prolonged PT-INR.
  • The effect of vitamin K administration on PT-INR in these patients has not been thoroughly investigated.

Purpose of the Study:

  • To evaluate changes in PT-INR in response to vitamin K administration in critically ill patients with PT-INR between 1.3 and 1.9.

Main Methods:

  • A registry study matched 129 critically ill patients receiving vitamin K with 129 controls using propensity scores.
  • PT-INR was measured before and 12-36 hours after vitamin K administration.
  • Exclusion criteria included liver cirrhosis and recent blood transfusions.

Main Results:

  • PT-INR decreased in both the vitamin K group and the control group.
  • The decrease in PT-INR was slightly more pronounced in patients who received vitamin K (p = 0.01).

Conclusions:

  • Vitamin K administration resulted in a slightly larger PT-INR decrease in critically ill patients with PT-INR 1.3-1.9 compared to controls.
  • Future studies should identify patient populations benefiting from vitamin K and compare its efficacy to plasma or prothrombin complex concentrate.
Abstract

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
115
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
88
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
139
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
96
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
124